Should I Buy APRE? APRE 2026 Analysis

Should You Buy Aprea Therapeutics Inc (APRE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.750

1 Day change

-5.65%

52 Week Range

4.650

Analysis Updated At

2026/01/28

APRE is not a good buy right now for a Beginner long-term investor deploying $50k–$100k. The stock is in a clear downtrend, fundamentals show minimal revenue with ongoing losses, and there are no proprietary buy signals or near-term news momentum to support an impatient entry. Best action: avoid initiating a new position (hold only if already owned and willing to tolerate high biotech trial risk).

Technical Analysis

Price/Trend: Pre-market at 0.869 (+4.83%) but still below the pivot (0.884), with bearish alignment across moving averages (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. Momentum: MACD histogram is below 0 and negatively contracting—selling pressure may be easing slightly, but momentum remains bearish. RSI: RSI(6) at 29.7 is near oversold territory, which can allow short bounces, but oversold conditions in a downtrend are not a reliable long-term entry signal. Levels: Support at 0.811 (S1) then 0.766 (S2). Resistance at 0.956 (R1) then 1.001 (R2). With price below pivot, resistance overhead is a near-term headwind. Pattern-based forward look: Similar-pattern stats imply modest upside odds short-term (next day/week) but a negative bias over the next month (-5.42%), consistent with the broader bearish structure. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

Potential strategic upside from shifting toward combination strategies (if early data supports it).

Neutral/Negative Catalysts

Strong bearish trend (MA stack bearish; price below pivot; MACD still negative) increases odds that rallies fade.
Latest financials show extremely low revenue and ongoing losses (typical early biotech risk, but unfavorable for a beginner long-term allocation).
No recent news flow in the last week to attract incremental buyers.
No meaningful positive hedge fund/insider accumulation signals (both described as neutral).
No supportive congress/politician trading signal (no recent congress trading data available).

Financial Performance

Latest quarter: 2025/Q3. Revenue fell to 1,848 (-99.48% YoY), indicating effectively minimal operating revenue. Net income was -2,972,410 (loss; -21.44% YoY), and EPS was -0.47 (-26.56% YoY). Gross margin listed at 100 (no change YoY), which isn’t very informative here given the tiny revenue base. Overall, the quarter reflects a pre-commercial biotech profile: negligible revenue and continued losses without clear signs of improving operating momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend: H.C. Wainwright maintained a Buy rating (2025-12-18) but sharply cut the price target from $20 to $5 after a pipeline/corporate outlook update and a strategic shift away from ATRN-119 monotherapy toward combination approaches, with APR-1051 now driving their valuation. Wall Street pro view (pros/cons): Pros—still a Buy with identifiable clinical catalysts (Q1 data update) and a more focused lead program (APR-1051). Cons—the magnitude of the price-target cut signals materially lowered expectations and higher uncertainty; the investment case is heavily dependent on early-stage clinical outcomes.

2 Analyst Rating

Wall Street analysts forecast APRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APRE is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.796

Low

Averages

High

Current: 0.796

Low

Averages

High

H.C. Wainwright

Joseph Pantginis

Buy

downgrade

$5 -> $4

AI Analysis

2026-01-29

New

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$5 -> $4

AI Analysis

2026-01-29

New

downgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Aprea Therapeutics to $4 from $5 and keeps a Buy rating on the shares. The firm is "encouraged by the positive," early proof-of-concept data from the ACESOT-1051 study. Aprea reported "promising" preliminary signals from an endometrial cancer patient, the analyst tells investors in a research note. H.C. Wainwright cites dilution for the target cut.

H.C. Wainwright

Buy

downgrade

$20 -> $5

2025-12-18

Reason

H.C. Wainwright

Price Target

$20 -> $5

2025-12-18

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Aprea Therapeutics to $5 from $20 and keeps a Buy rating on the shares after Aprea provided an update on its pipeline progress and corporate outlook for 2026. The company will be shifting focus from its monotherapy study of ATRN-119 to focus on potential combination strategies, notes the analyst, who is adjusting focus to APR-1051, which now provides 100% of the valuation contribution to the firm's model. APR-1051 is currently being evaluated in the ongoing Phase 1 ACESOT-1051 dose-escalation trial and near term catalysts include updated safety and efficacy data due in Q1 and completion of dose escalation expected in 2026, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APRE

Unlock Now

APRE Should I Buy

APRE Should I Buy

Should You Buy Aprea Therapeutics Inc (APRE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch